Table 2.
Comparison of clinical and biochemical parameters between groups according to sST2 value.
| Parameter | sST2 ≤ 45.8 (n = 74) |
sST2 > 45.8 (n = 36) |
p |
|---|---|---|---|
| Age (years) | 53.0 ± 11.7 | 53.4 ± 11.0 | 0.7488 |
| Men | 89.20% | 91.70% | 0.6844 |
| BMI (kg/m2) | 28.9 ± 4.8 | 26.6 ± 3.7 | 0.0146 |
| SBP (mmHg) | 110.1 ± 16.3 | 104.9 ± 12.6 | 0.1808 |
| DBP (mmHg) | 72.2 ± 9.5 | 66.9 ± 8.1 | 0.0090 |
| LVEF (%) | 23.9 ± 8.0 | 21.9 ± 7.6 | 0.2595 |
| Duration of HF (months) | 101.5 ± 92.1 | 83.7 ± 72.7 | 0.5155 |
| Etiology of HF—CAD | 49% | 56% | 0.2950 |
| Etiology of HF—DCM | 50% | 39% | 0.2950 |
| NYHA class | 2.4 ± 0.6 | 2.6 ± 0.5 | 0.2164 |
| ICD | 50% | 39% | 0.2950 |
| CRT-D | 50% | 39% | 0.2950 |
| Comorbidities | |||
| AF | 9.50% | 30.60% | 0.0039 |
| Arterial hypertension | 47.30% | 38.90% | 0.405 |
| Diabetes mellitus type II | 21.60% | 33.30% | 0.3411 |
| Thyroid disease | 17.60% | 22.20% | 0.56 |
| COPD | 12.20% | 13.90% | 0.7987 |
| Smoking at admission | 10.80% | 16.70% | 0.5877 |
| Smoking history | 54.10% | 55.60% | 0.5877 |
| Biochemical parameters | |||
| WBC (109/L) | 7.3 ± 1.9 | 8.3 ± 2.0 | 0.002 |
| RBC (1012/L) | 4.7 ± 0.4 | 4.8 ± 0.6 | 0.9368 |
| HGB (mmol/L) | 9.0 ± 0.7 | 8.9 ± 0.8 | 0.2094 |
| RDW (%) | 15.0 ± 4.9 | 15.8 ± 1.7 | 0.0001 |
| PLT (109/L) | 197.8 ± 51.2 | 210.3 ± 55.7 | 0.2437 |
| ESR (mm/h) | 8.2 ± 7.3 | 12.4 ± 14.4 | 0.422 |
| CRP (mg/L) | 2.6 ± 3.1 | 8.2 ± 12.4 | <0.001 |
| Na+ (mmol/L | 140.0 ± 2.1 | 137.9 ± 3.2 | 0.0005 |
| K+ (mmol/L) | 4.6 ± 2.4 | 4.2 ± 0.6 | 0.1958 |
| Creatinine (umol/L) | 101.2 ± 25.0 | 106.7 ± 21.9 | 0.2872 |
| Fasting glucose (mmol/L) | 6.5 ± 2.7 | 6.4 ± 1.7 | 0.5155 |
| NT-proBNP (pg/mL) | 1477.0 ± 1702.8 | 3862.9 ± 5909.3 | <0.001 |
| TSH (uIU/mL) | 1.9 ± 1.7 | 2.0 ± 1.8 | 0.9671 |
| CPET parameters | |||
| Peak VO2 (mL/kg/min) | 18.1 ± 5.5 | 15.8 ± 4.1 | 0.062 |
| Peak VO2 (L/min) | 1.6 ± 0.6 | 1.3 ± 0.3 | 0.003 |
| Peak VO2 (%) | 56.5 ± 16.0 | 49.5 ± 15.2 | 0.0095 |
| VE/VCO2 slope | 31.6 ± 6.9 | 35.7 ± 8.1 | 0.0188 |
| PETCO2 (mmHg) | 34.6 ± 5.8 | 29.7 ± 6.0 | <0.001 |
| Medications | |||
| Beta-blocker | 98.70% | 97.20% | 0.5993 |
| ACE-I/ARB | 82.40% | 83.30% | 0.9066 |
| ARNI | 12.20% | 5.60% | 0.2784 |
| MRA | 86.50% | 88.90% | 0.7227 |
| Loop diuretic | 89.20% | 91.70% | 0.6844 |
BMI—body mass index; SBP—systolic blood pressure; DBP—diastolic blood pressure; NYHA—New York Heart Association; HF—heart failure; CAD—coronary artery disease; DCM—dilated cardiomyopathy; ICD—implantable cardioverter-defibrillator; CRT-D—cardiac resynchronization therapy defibrillator; AF—atrial fibrillation; COPD—chronic obstructive pulmonary disease; WBC—white blood cells; RBC—red blood cells; HGB—hemoglobin; RDW—red blood cell distribution width; PLT—platelets; ESR—erythrocyte sedimentation rate; CRP—C-reactive protein; Na+—sodium; K+—potassium; NT-proBNP—N-terminal prohormone of brain natriuretic peptide; TSH—thyrotropin; Peak VO2—peak oxygen consumption; VE/VCO2 slope—minute ventilation/carbon dioxide production; PETCO2—partial pressure of end-tidal carbon dioxide; LVEF—left ventricle ejection fraction; ACE-I—angiotensin-converting enzyme inhibitors; ARB—angiotensin II receptor blocker; ARNI—angiotensin receptor neprilysin inhibitor; MRA—mineralocorticoid receptor antagonist.